Market News

PepsiCo Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street’s Most Accurate Analysts – PepsiCo (NASDAQ:PEP)






PepsiCo Anticipates Strong Q3 Earnings Growth Amid Analyst Forecast Updates

PepsiCo’s Earnings Forecast for Q3 Unveiled

PepsiCo, Inc. PEP is set to disclose its third-quarter earnings before the market opens on Tuesday, Oct. 8.

Financial analysts are projecting earnings of $2.30 per share for the quarter, showing an increase from $2.25 per share reported in the same period last year. It is also anticipated that PepsiCo will announce revenue of $23.85 billion compared to $23.45 billion in the previous year, according to data from Benzinga Pro.

Furthermore, on Oct. 1, PepsiCo revealed its definitive agreement to acquire Garza Food Ventures LLC, known as Siete Foods, for a substantial $1.2 billion.

In Monday’s trading session, PepsiCo shares experienced a modest 0.5% decline, closing at $167.21.

For further insights into analyst ratings, Benzinga readers can refer to the Analyst Stock Ratings page, where these ratings are categorized by several variables including stock ticker, company name, analyst firm, and rating change.

Let’s delve into the recent assessments from Benzinga’s most precise analysts regarding PepsiCo.

  • B of A Securities analyst Bryan Spillane maintained a Buy rating on Sept. 30, reducing the price target from $190 to $185. This analyst boasts an accuracy rate of 68%.
  • Morgan Stanley analyst Dara Mohsenian downgraded the stock from Overweight to Equal-Weight on Sept. 20, setting a price target of $185. Mohsenian holds an accuracy rate of 73%.
  • Barclays analyst Lauren Lieberman sustained an Overweight rating but adjusted the price target from $187 to $186 on Oct. 4. This analyst’s accuracy rate stands at 61%.
  • Wells Fargo analyst Chris Carey adhered to an Equal-Weight rating while revising the price target from $175 to $170 on July 10. Carey’s accuracy rate is 65%.
  • TD Cowen analyst Robert Moskow upheld a Buy rating but decreased the price target from $200 to $190 on July 3. Moskow’s accuracy rate is 66%.
See also  Taysha Gene Therapies: A Spark in the Market Taysha Gene Therapies: A Spark in the Market

Curious About Investing in PEP Stock? Here’s Analyst Perspective:


Further Reading:

Market News and Data brought to you by Benzinga APIs